Equities

Allergy Therapeutics PLC

AGY:LSE

Allergy Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.90
  • Today's Change-1.00 / -8.40%
  • Shares traded512.78k
  • 1 Year change72.47%
  • Beta1.4518
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Allergy Therapeutics PLC's net income fell 3.91% from a loss of 38.62m to a larger loss of 40.13m despite relatively flat revenues.
Gross margin53.23%
Net profit margin-72.91%
Operating margin-58.89%
Return on assets-59.92%
Return on equity--
Return on investment-91.26%
More ▼

Cash flow in GBPView more

In 2025, Allergy Therapeutics PLC did not generate a significant amount of cash. Cash Flow from Financing totalled 31.16m or 56.61% of revenues. In addition the company used 28.11m for operations while cash used for investing totalled 2.89m.
Cash flow per share-0.0075
Price/Cash flow per share--
Book value per share-0.0059
Tangible book value per share-0.0068
More ▼

Balance sheet in GBPView more

Allergy Therapeutics PLC has a Debt to Total Capital ratio of 188.39%, a lower figure than the previous year's 392.50%.
Current ratio1.28
Quick ratio0.7635
Total debt/total equity--
Total debt/total capital1.88
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items increased 18.41%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		20.34
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.